主页实验库实验详情

E-GEOD-22358 GSE22358 transcription profiling by array Homo sapiens

Clinical and Pathologic Response of the Primary Tumor in Women Receiving Neoadjuvant Docetaxel-Capecitabine (+/- Trastuzumab) Chemotherapy

·发布 2011年3月18日 ·更新 2014年5月1日

316

样本数

158

实验数

芯片平台

相关文献

实验描述

Results: In subjects who completed treatment and surgery, the pCR and near-complete response rates were 15.8% in HER2-negative and 50% in HER2-positive subjects. When stratified by genomic subtype, subjects of the HER2-enriched subtype had the best response (66.7%), the luminal A (11%) and B (4.8%) subtypes the poorest. Of 147 patients tested for p53 mutations using the AmpliChip test, 78 variants were detected; 55 were missense. The response rate among TP53 mutated patients was 30%, significantly higher than the rate in TP53 wild-type patients (10%, P = .0032). Concordance between AmpliChip mutation status versus IHC staining was 65%, with AmpliChip status being predictive of response and IHC status being not being predictive. Conclusion: Capecitabine plus docetaxel in HER2-negative subjects, and with trastuzumab in HER2-positive subjects, provided a good response rate with fewer cycles. p53 mutational analysis using the AmpliChip p53 assay, and genomic subtyping using the PAM50 assay, were promising predictive tests of response. reference x sample

参考文献

TP53 genomics predict higher clinical and pathologic tumor response in operable early-stage breast cancer treated with docetaxel-capecitabine ± trastuzumab.

Glück S, Ross JS, Royce M, McKenna EF Jr, Perou CM, Avisar E, Wu L

PMID: 21373875

芯片平台

A-GEOD-5325

Agilent UNC Perou Lab Homo sapiens 1X44K Custom Array（158 例）

样本属性

BioSourceProvider

Stratagene

er (0 = negative; 1 = positive)

---, 0, 1

grade

---, 1, 2, 3

her2 (0 = negative; 1 = positive)

0, 1

intrinsic subtypes by pam50

Basal, Her2, LumA, LumB, Normal

neoadjuvant chemotherapy

(docetaxel-Capecitabine)+ Trastuzumab, docetaxel-Capecitabine

Organism

Homo sapiens

p53 measured by ihc

---, NEGATIVE, POSITIVE, UNDETERMINED

p53 status by amplichip

---, MUTANT, WILDTYPE

pgr (0 = negative; 1 = positive)

---, 0, 1

reference

Stratagene Human Universal Reference that contained 1/10 added MCF7 and ME16C RNAs

response

---, COMPLETE RESPONSE, NEAR COMPLETE RESPONSE, NO RESPONSE, PARTIAL RESPONSE

sample

G1604, G719749, G719755, G963149, G963156, H021105, H021107, H021108, H349179, H349186, H516396, H516397, H516398, H516949, H516956, H629717, H629718, H629719, H672896, H672898, H672906, H718159, H718165, H957385, H957386, H957387, H957549, H957556, I130528, I130529, I130567, I130568, I130598, I130607, I258318, I258319, I258325, I383207, I383208, I383209, I491936, I491937, I491938, I612036, I612038, I633488, I695766, I824997, I824998, I825006, I825007, I831437, I962239, I962245, I962246, I962247, I962249, J018786, J018787, J018788, J168308, J168899, J168936, J168937, J168938, J460617, J460619, J470138, J472756, J472757, J472758, J547636, J560829, J560835, J560837, J762326, J762328, J915509, K121818, K205578, K205585, K280817, K280818, K282369, K282376, K282377, K282378, K282379, K320417, K440086, K826609, K826616, K826617, K892968, K900446, K900448, L027366, L432757, L432758, L432759, L444938 weak, L444939, L444946, L525226, L525227, L737586, L737587, L737588, L768267, L768268, L775237, L799207 weak, L831386, L831387, L831388, M200489, M200496, M200498, M228987, M228988, M228989, M228995, M255438, M256097, M256098, M256106, M308595, M308596, M308598, M692279, M906756-weak, N123517, N178817, N178818, N302589, N302595, N399197, N399199, N435237, N820416, N820418, N843157, N843158, N844748, N852648, N852649, N995039, O219015, O219016, O219017 weak, O393719, P332305, P553317, P553318

slidename

H1AUNC44K-H1-0001, H1AUNC44K-H1-0002, H1AUNC44K-H1-0003, H1AUNC44K-H1-0004, H1AUNC44K-H1-0006, H1AUNC44K-H1-0007, H1AUNC44K-H1-0008, H1AUNC44K-H1-0010, H1AUNC44K-H1-0011, H1AUNC44K-H1-0012, H1AUNC44K-H1-0014, H1AUNC44K-H1-0015, H1AUNC44K-H1-0016, H1AUNC44K-H1-0021, H1AUNC44K-H1-0022, H1AUNC44K-H1-0023, H1AUNC44K-H1-0024, H1AUNC44K-H1-0025, H1AUNC44K-H1-0026, H1AUNC44K-H1-0027, H1AUNC44K-H1-0029, H1AUNC44K-H1-0030, H1AUNC44K-H1-0031, H1AUNC44K-H1-0032, H1AUNC44K-H1-0033, H1AUNC44K-H1-0034, H1AUNC44K-H1-0035, H1AUNC44K-H1-0036, H1AUNC44K-H1-0037, H1AUNC44K-H1-0038, H1AUNC44K-H1-0039, H1AUNC44K-H1-0041, H1AUNC44K-H1-0051, H1AUNC44K-H1-0052, H1AUNC44K-H1-0053, H1AUNC44K-H1-0054, H1AUNC44K-H1-0056, H1AUNC44K-H1-0057, H1AUNC44K-H1-0058, H1AUNC44K-H1-0059, H1AUNC44K-H1-0060, H1AUNC44K-H1-0061, H1AUNC44K-H1-0064, H1AUNC44K-H1-0065, H1AUNC44K-H1-0066, H1AUNC44K-H1-0067, H1AUNC44K-H1-0068, H1AUNC44K-H1-0069, H1AUNC44K-H1-0070, H1AUNC44K-H1-0097, H1AUNC44K-H1-0098, H1AUNC44K-H1-0099, H1AUNC44K-H1-0100, H1AUNC44K-H1-0111, H1AUNC44K-H1-0112, H1AUNC44K-H1-0113, H1AUNC44K-H1-0114, H1AUNC44K-H1-0115, H1AUNC44K-H1-0116, H1AUNC44K-H1-0118, H1AUNC44K-H1-0119, H1AUNC44K-H1-0120, H1AUNC44K-H1-0121, H1AUNC44K-H1-0122, H1AUNC44K-H1-0123, H1AUNC44K-H1-0124, H1AUNC44K-H1-0125, H1AUNC44K-H1-0126, H1AUNC44K-H1-0127, H1AUNC44K-H1-0128, H1AUNC44K-H1-0129, H1AUNC44K-H1-0130, H1AUNC44K-H1-0141, H1AUNC44K-H1-0142, H1AUNC44K-H1-0143, H1AUNC44K-H1-0145, H1AUNC44K-H1-0146, H1AUNC44K-H1-0147, H1AUNC44K-H1-0148, H1AUNC44K-H1-0149, H1AUNC44K-H1-0150, H1AUNC44K-H1-0161, H1AUNC44K-H1-0171, H1AUNC44K-H1-0172, H1AUNC44K-H1-0174, H1AUNC44K-H1-0175, H1AUNC44K-H1-0186, H1AUNC44K-H1-0187, H1AUNC44K-H1-0188, H1AUNC44K-H1-0189, H1AUNC44K-H1-0190, H1AUNC44K-H1-0324, H1AUNC44K-H1-0325, H1AUNC44K-H1-0326, H1AUNC44K-H1-0327, H1AUNC44K-H1-0328, H1AUNC44K-H1-0329, H1AUNC44K-H1-0330, H1AUNC44K-H1-0331, H1AUNC44K-H1-0332, H1AUNC44K-H1-0351, H1AUNC44K-H1-0352, H1AUNC44K-H1-0353, H1AUNC44K-H1-0354, H1AUNC44K-H1-0355, H1AUNC44K-H1-0356, H1AUNC44K-H1-0357, H1AUNC44K-H1-0358, H1AUNC44K-H1-0359, H1AUNC44K-H1-0361, H1AUNC44K-H1-0362, H1AUNC44K-H1-0363, H1AUNC44K-H1-0365, H1AUNC44K-H1-0366, H1AUNC44K-H1-0367, H1AUNC44K-H1-0368, H1AUNC44K-H1-0369, H1AUNC44K-H1-0370, H1AUNC44K-H1-0371, H1AUNC44K-H1-0372, H1AUNC44K-H1-0373, H1AUNC44K-H1-0374, H1AUNC44K-H1-0375, H1AUNC44K-H1-0376, H1AUNC44K-H1-0377, H1AUNC44K-H1-0378, H1AUNC44K-H1-0379, H1AUNC44K-H1-0421, H1AUNC44K-H1-0422, H1AUNC44K-H1-0431, H1AUNC44K-H1-0432, H1AUNC44K-H1-0433, H1AUNC44K-H1-0435, H1AUNC44K-H1-0436, H1AUNC44K-H1-0437, H1AUNC44K-H1-0438, H1AUNC44K-H1-0439, H1AUNC44K-H1-0497, H1AUNC44K-H1-0498, H1AUNC44K-H1-0499, H1AUNC44K-H1-0500, H1AUNC44K-H1-0501, H1AUNC44K-H1-0504, H1AUNC44K-H1-0505, H1AUNC44K-H1-0506, H1AUNC44K-H1-0507, H1AUNC44K-H1-0508, H1AUNC44K-H1-0509, H1AUNC44K-H1-0510, H1AUNC44K-H1-0511, H1AUNC44K-H1-0512, H1AUNC44K-H1-0513, H1AUNC44K-H1-0514, H1AUNC44K-H1-0515

study

Xena

tissue

normal breast

tumor size (cm)

10, 10.5, 11, 12, 13, 13.3, 14, 14.5, 2, 2.2, 2.5, 2.7, 2.8, 3, 3.4, 3.5, 3.7, 35, 4, 4.5, 4.8, 5, 5.1, 5.3, 5.4, 5.5, 6, 6.1, 6.2, 6.3, 6.5, 6.8, 7, 7.5, 7.7, 8, 8.5, 8.7, 9, 9.5

实验信息

登记号

E-GEOD-22358

GEO 编号

GSE22358

实验类型

transcription profiling by array

物种

Homo sapiens

发布日期

2011年3月18日

更新日期

2014年5月1日

提交者

Charles Perou、 Charles M Perou、 Stepan Gluck、 Lin Wu

外部链接

ArrayExpress 原始页 NCBI GEO：GSE22358

分析服务

Clinical and Pathologic Response of the Primary Tumor in Women Receiving Neoadjuvant Docetaxel-Capecitabine (+/- Trastuzumab) Chemotherapy

联系地址

微信公众号